Cardiology

Already approved by the FDA for the treatment of the polyneuropathy of hATTR amyloidosis, the August 3rd announcement of APOLLO-B results from Alnylam Pharmaceuticals suggests patisiran (ONPATTRO) could be a safe and efficacious treatment option for patients with ATTR amyloidosis with cardiomyopathy.

In his most recent column, Dr. Gregory Weiss provides perspective on a recent Icahn School of Medicine-led study examining the impact of environmental exposures on risk of cardiovascular disease.

A study of more than 60,000 patients with gout provides insight into the apparent increase in risk of cardiovascular events observed in the months immediately following a gout flare.

Dapagliflozin consistently reduced the risk of CV death or HHF, HHF alone, and progression of kidney disease regardless of background use of CV medications, investigators say.

The age-adjusted mortality rates for heart failure in young adults increased from 2.36 in 1999 to 3.16 in 2019.

An analysis of data from a pair of major studies provides insight into the use of a traditional 30-year risk score against a polygenic risk score for predicting coronary heart disease based on risk score across multiple age groups

At the 2022 ASPC annual meeting, Dr. Gluckman highlights the overall impact of the economic cost of cardiovascular disease and the role of prevention.

Dr. Kushner discusses obesity as a risk factor for CVD and how preventive cardiologists can better target weight management to support patient health.

An analysis of EHR data provides insight into the apparent increase in risk of developing cardiovascular disease or diabetes in the weeks immediately proceeding a COVID-19 infection.

Undergoing androgen deprivation therapy as part of treatment for prostate cancer was linked to a more than 2-fold increase in risk of cardiovascular disease-related death, according to a new study.

The new recommendation acknowledges the role of disease-preventive behaviors that can be taken on by approximately 12% of the US population.

On July 26, the US Preventive Services Task Force released an updated recommendation statement outlining the organization's stance on behavioral counseling aimed at improving diet and physical activity in adults without cardiovascular risk factors, which was awarded a level C recommendation and is consistent with their 2017 recommendations on the topic.

Our latest case report from Brady Pregerson, MD, features a man in his mid-70s with a history of AFib on warfarin and a recent CABG brought in by ambulance with worsening chest pain and shortness of breath. Can you determine the correct diagnosis?

Data from a major trial detail the cardiorenal benefits of dapagliflozin use among patients with type 2 diabetes based on use of background cardiovascular medications.

Though current use rates have declined since 2017, investigators believe more young adults are transitioning from experimental to habitual use.

The 2022 scientific sessions in Louisville, Kentucky will emphasize inclusiveness and the care for all at risk for cardiovascular disease.

An analysis of real-world EHR data from more than 900,000 statin users suggests use of rosuvastatin was associated with an 8% greater risk of hematuria, a 17% greater risk of proteinuria, and a 15% higher risk of developing kidney failure requiring replacement therapy such as dialysis or transplantation compared to atorvastatin use.

An analysis of the EPIC-Norfolk cohort suggests a potassium-rich diet could contribute to lowered blood pressure and reduced risk of cardiovascular disease events in women.

Women with endometriosis had a 34% greater risk of stroke than women without the chronic inflammatory gynecological condition, according to an analysis of the Nurses Health Study II.

An analysis of data from the ARIC study provides insight into the impact of genetic risk scores on lifetime risk of stroke and how optimal cardiovascular health might influence this risk.

Compared to use of atorvastatin, use of rosuvastatin was associated with an 8% greater risk of hematuria, a 17% greater risk of proteinuria, and a 15% higher risk of developing kidney failure.

An analysis of data from more than 450,000 patients in the UK details an 81% increase in the net incidence of diabetes in the first 4 weeks after contracting COVID-19, which remained elevated through weeks 5-12, compared to those who did not contract COVID-19.

An analysis of patients with CKD from the CRIC study demonstrates those with the highest levels of physical activity had reductions in risk of 36%, 29%, and 53% for atherosclerotic events, incident heart failure, and cardiovascular mortality, respectively, compared to those with the lowest levels.

Early follow-up in patients with COPD led to lower rates of readmissions at 90 days, while patients with CHF saw lower 90-day mortality.

Nearly half of the study cohort did not fill a statin prescription within 90 days after an ASCVD event.